1,215 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bought by Canada Post Corp Registered Pension Plan

Canada Post Corp Registered Pension Plan purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 1,215 shares of the biopharmaceutical company’s stock, valued at approximately $865,000.

Several other institutional investors have also added to or reduced their stakes in the company. Norges Bank bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at about $802,036,000. Amundi increased its holdings in Regeneron Pharmaceuticals by 45.8% during the 4th quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company’s stock valued at $1,138,074,000 after purchasing an additional 487,489 shares during the period. Loomis Sayles & Co. L P increased its holdings in Regeneron Pharmaceuticals by 33.4% during the 4th quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company’s stock valued at $1,122,168,000 after purchasing an additional 393,997 shares during the period. Proficio Capital Partners LLC raised its position in Regeneron Pharmaceuticals by 92,865.3% during the 4th quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company’s stock valued at $156,284,000 after purchasing an additional 219,162 shares during the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Regeneron Pharmaceuticals by 6.8% in the 4th quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company’s stock worth $1,726,940,000 after buying an additional 155,369 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ:REGN opened at $571.06 on Tuesday. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $62.43 billion, a PE ratio of 14.92, a price-to-earnings-growth ratio of 2.34 and a beta of 0.44. The firm’s 50 day moving average price is $657.03 and its 200-day moving average price is $749.93. Regeneron Pharmaceuticals, Inc. has a twelve month low of $525.99 and a twelve month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter last year, the company posted $11.86 EPS. The company’s revenue was up 10.3% compared to the same quarter last year. Equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.62%. The ex-dividend date of this dividend was Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 2.30%.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on REGN shares. Citigroup decreased their target price on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a report on Tuesday, January 28th. Bernstein Bank reduced their price target on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. The Goldman Sachs Group decreased their price objective on Regeneron Pharmaceuticals from $1,019.00 to $917.00 and set a “buy” rating for the company in a report on Monday. Robert W. Baird dropped their price target on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 5th. Finally, UBS Group lowered Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $1,130.00 to $738.00 in a research report on Thursday, January 16th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, eighteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $964.88.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.